Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
March 21 2022 - 5:36PM
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage
biopharmaceutical company focused on discovering, developing, and
commercializing gene therapies to cure blindness diseases and
developing a vaccine to save lives from COVID-19, today announced
the appointment of Jessica Crespo, CPA, as Chief Accounting
Officer and Senior Vice President, Finance. She assumed the role
effective March 18, 2022.
In this role, she will be responsible for the development and
execution of the Company’s financial strategy, as well as all
corporate finance, accounting, and internal and external financial
reporting functions. She will serve as a member of Ocugen’s
management team, reporting directly to the CEO.
Ms. Crespo has more than 20 years of experience in accounting
and financial leadership. She has been with Ocugen since 2019,
previously serving as Vice President, Corporate Controller and
Treasurer. Before joining the Company, she held financial
leadership roles within Aerie Pharmaceuticals, Aralez
Pharmaceuticals and Cubist Pharmaceuticals where she was
responsible for financial and technical accounting and SEC
reporting, including the implementation of new accounting standards
and the accounting and reporting of complex transactions. Prior to
that, Ms. Crespo was a senior manager in Ernst & Young’s audit
and assurance practice.
“Jess has been an important member of the Ocugen team for nearly
three years and we are pleased to recognize her valuable
contributions with this expansion of her role. The Company has seen
transformational growth over the past year, as we work to advance
the therapies in our pipeline toward regulatory approval. Jess’
knowledge and expertise will help us sustain that momentum,” said
Dr. Shankar Musunuri, Chairman of the Board, Chief Executive
Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston
College and is a Certified Public Accountant.
About Ocugen, Inc.Ocugen, Inc. is a
clinical-stage biopharmaceutical company focused on discovering,
developing, and commercializing gene therapies to cure blindness
diseases and developing a vaccine to save lives from COVID-19. Our
breakthrough modifier gene therapy platform has the potential to
treat multiple retinal diseases with one drug — “one to many,” and
our novel biologic product candidate aims to offer better therapy
to patients with underserved diseases such as wet age-related
macular degeneration, diabetic macular edema, and diabetic
retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine
candidate for COVID-19 in the U.S. and Canadian markets. For more
information, please visit www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (“SEC”), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Ocugen Contact: Ken
InchaustiHead, Investor Relations &
CommunicationsIR@Ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024